You are here

  • Home
  • Archive
  • Volume 75, Issue 6
  • Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Article metrics

Article menu
XML
Clinical and epidemiological research
Extended report
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

 

Online download statistics by month:

Online download statistics by month: January 2016 to February 2023

AbstractFullPdf
Jan 2016735333344
Feb 20161111382552
Mar 2016233292272
Apr 2016110388211
May 20161140327407
Jun 2016613333314
Jul 2016301115111
Aug 2016188133121
Sep 201610896120
Oct 2016149135208
Nov 2016128116101
Dec 201614969138
Jan 20171107995
Feb 20172311582
Mar 20177140108
Apr 2017218770
May 2017219661
Jun 20174215786
Jul 201717817768
Aug 201716016064
Sep 201718017981
Oct 201721921567
Nov 201719119283
Dec 201712312360
Jan 201818919054
Feb 201819217774
Mar 201820420568
Apr 201817317449
May 201817217452
Jun 201816116462
Jul 201813713748
Aug 201813213235
Sep 201813913939
Oct 201818418259
Nov 201817117148
Dec 201811911930
Jan 201915515258
Feb 201910610629
Mar 201913613449
Apr 2019918951
May 201911611656
Jun 2019797922
Jul 201910410040
Aug 20191039544
Sep 2019847932
Oct 201911510658
Nov 2019988652
Dec 2019999949
Jan 2020939051
Feb 2020805948
Mar 2020675962
Apr 2020625052
May 2020938146
Jun 2020917139
Jul 20209291107
Aug 2020716337
Sep 2020635446
Oct 20201149053
Nov 20201058767
Dec 20201179349
Jan 202111810849
Feb 2021978332
Mar 2021978945
Apr 2021746438
May 2021988944
Jun 2021868635
Jul 2021707034
Aug 2021979737
Sep 2021939340
Oct 2021908462
Nov 2021898048
Dec 2021928231
Jan 2022978937
Feb 2022736923
Mar 202213212435
Apr 20221079344
May 202213714671
Jun 202211311637
Jul 202212310937
Aug 202214613449
Sep 202216515438
Oct 202214513149
Nov 2022958734
Dec 202211810725
Jan 202311210027
Feb 202315815327
Total13331113696667